Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Busting out now!
I'm feeling good about APYP...patience here will pay off...JMHO
Sure could use some news...lol...spiraling down...down...down...I want UP! UP! UP!...lol
Who!? What!? When!? Where!? Why!?...lol
sure could use a PR soon
I plan on accumulating at these rock bottom prices. I suffer from sleep apnea myself and know several others in my family and close friends that do as well. This area is really an untapped market with tons of potential. I will sit on my shares until this breaks wide open...after all... how many people really do sleep well after the age of 45 and beyond....sooooo many Baby Boomers out there....no brainer...lol...melatonin just doesn't cut it!
this thing is all over the place today...got some at .0037
when my funds clear ...hopefully by Friday...I'm adding 10 Mil shares at these rock bottom prices...I'm a patient man...this is a no brainer
I'll buy back in at .40...who knows, maybe this goes down to a quarter.
what happens then? Sorry not a charts guy?
I agree!
This will be today's hottest ticker!
I'm sure whatever the wording issues the FDA has that ITRM will be "yessing" them to no end!...lol.
Agreed!
Hopefully ITRM is working diligently to address the labeling verbiage issue(s) the FDA brought up. I'm thinking ITRM has a team working to resolve this around the clock. I've been in pharma/med devices for 15 years and companies I worked at make something like this a 24/7 priority with no letting up. I believe both FDA and ITRM are still working to the target date of 7/25. GO ITRM!!!!
So is it logical to say that the FDA is ready to approve but just needing to work on the so called "label deficiencies" with ITRM which will probably and hopefully address the marketing/prescription/labeling verbiage on the drug product IFU or "instructions for usage"?
Keeping my fingers crossed for a big pay day in T minus(-) 11 days...business days that is!
I emailed investor relations last week and got no reply as of yet.
Buys coming in!
Yeah baby! KABOOM!
I agree...countdown =T minus 12 days...nowhere but up like a rocketship from here on until 7/25
H.C. Wainwright still positive on ITRM
https://seekingalpha.com/news/3713029-hc-wainwright-still-bullish-on-iterum-despite-friday-selloff
My gut tells me somethin's brewing here...coming back...thinkin' it's positive...we shall see. JMHO
Looks like confidence level is dropping here fast!
sorry for repeat...didn't think my 1st message posted.
Nice article on ITRM this morning on Seeking Alpha website.
https://seekingalpha.com/article/4437871-iterum-therapeutics-rates-a-speculative-buy
Gap up Tuesday...JMHO.
Nice, somewhat positive article out just today for ITRM on Seeking Alpha website. Gap up Tuesday...JMHO.
https://seekingalpha.com/article/4437871-iterum-therapeutics-rates-a-speculative-buy
JUST MY TAKE…
This letter, the company said, "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments at this time" for its antibiotic candidate sulopenem in treating uncomplicated urinary tract infections.
Key word =
pre·clude
/pr?'klo?od/
verb
1.prevent from happening; make impossible.
"the secret nature of his work precluded official recognition"
Similar: prevent
2.(of a situation or condition) prevent someone from doing something.
"his difficulties preclude him from leading a normal life"
My interpretation is that the “"identified deficiencies that (prevents the FDA) to continue to discuss labeling and post marketing requirements/commitments (only this part of the review) = (what ITRM needs to provide to FDA to satisfy) at this time for its antibiotic candidate sulopenem in treating uncomplicated urinary tract infections.
My interpretation is that the letter only involves the "labeling/marketing piece of the FDA review/process, not any deficiency in suboplenum efficacy testing, etc., that will negate approval.
Sounds more like what the appropriate verbiage should be regarding how product will be placed in the market based on drug requirements/regulations.
JMO
gonna be bumpy tomorrow...weeeee!
I'll buy some cheapies tomorrow...
3 years ago the IPO was $13....surely with FDA approval we might reach or exceed that....? Any thoughts anyone?
Sure wish I had some more cash on hand to buy at this pps.
The next few weeks are gonna be a heck of a lot of fun! $$$$
24 days...tick...tock...BOOM!!!
Right on brother!
Holding strong! Believers are Bullish! The Bulls Believe!
Nice comeback at end of day...but someone's playing with this. News soon will crush flippers.
It doesn't seem right that if the FDA is this close and has gone back to ITRM several times now for more information, that this wouldn't have been discussed or addressed by now. Might they still approve contingent upon a site visit?
Yeah...I'm thinking $7-$8 pps upon approval, and then if they hit us with partnership/distributor this could hit $12-$15 pps.
Good deal for him and a great deal for us to come soon!